Story perspectives

FDA Issues 90-Day Guidance to Accelerate Genome-Editing Therapies

6/4/2026

Summary

Story summary

FDA issued guidance on June 2, 2026 opening a 90-day period to speed development.
The guidance allows sponsors to use chemistry, manufacturing and controls (CMC) data and nonclinical/clinical information for somatic-cell genome-editing products.
FDA encourages attendance at INTERACT and pre-IND meetings when filing IND.
The agency says the approach may cover AAV, nanoparticle and cell therapies.
Vijay Kumar said sponsors must justify knowledge and it raises efficiency keeping safety and efficacy high.

1 of 1

Story summary

FDA issued guidance on June 2, 2026 opening a 90-day period to speed development.
The guidance allows sponsors to use chemistry, manufacturing and controls (CMC) data and nonclinical/clinical information for somatic-cell genome-editing products.
FDA encourages attendance at INTERACT and pre-IND meetings when filing IND.
The agency says the approach may cover AAV, nanoparticle and cell therapies.
Vijay Kumar said sponsors must justify knowledge and it raises efficiency keeping safety and efficacy high.